ImmunoPrecise, Zymeworks partner on SARS-CoV-2 antibody

By The Science Advisory Board staff writers

September 17, 2020 -- ImmunoPrecise and Zymeworks announced that they have formed a research collaboration to develop a multispecific SARS-CoV-2 antibody.

Under the agreement, ImmunoPrecise will use Zymeworks' Azymetric and Efect platforms to further develop multiple COVID-19 monospecific antibody candidates by transforming them into bispecific and multispecific antibodies, the companies said.

Copyright © 2020

MemberID or email address:  

Forgot your password?